Physician profile
David Dunn
NPI 1275560088
$14,601.69
in general payments reported to CMS, 2019-2025
54 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $2,283 · 2021: $2,423 · 2022: $2,238 · 2023: $2,082 · 2024: $1,476 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,077 · Education: $53.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,076.96 |
| Education | $53.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,834.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,782.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,670.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.72 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $922.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $596.71 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $564.91 | 2019-2025 | |
| Antares Pharma, INC. | $520.16 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $488.71 | 2019-2022 | |
| Amgen INC. | $461.89 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $437.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.51 | 2019-2023 | Trintellix |
| Corcept Therapeutics | $396.14 | 2022-2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $341.12 | 2019-2023 | Xyosted, Qelbree |
| Currax Pharmaceuticals LLC | $303.60 | 2019-2023 | Nexletol, Contrave, Nexlizet |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.